Article Sidebar
Article Details
Copyright remains in the Author’s name. The work is licensed under a Creative Commons Attribution - Noncommercial Works License. Authors are required to complete and sign an Author Agreement form that outlines Author and Publisher rights and terms of publication. The Agreement form should be uploaded along with other submissions files and any submission will be considered incomplete without it [forthcoming].
Material submitted for publication in the SAMJ is accepted provided it has not been published or submitted for publication elsewhere. Please inform the editorial team if the main findings of your paper have been presented at a conference and published in abstract form, to avoid copyright infringement. The SAMJ does not hold itself responsible for statements made by the authors.
Previously published images
If an image/figure has been previously published, permission to reproduce or alter it must be obtained by the authors from the original publisher and the figure legend must give full credit to the original source. This credit should be accompanied by a letter indicating that permission to reproduce the image has been granted to the author/s. This letter should be uploaded as a supplementary file during submission.
Main Article Content
Adult pneumacoccal vaccination guideline
Abstract
Objective. To outline a rational cost-effective protocol for pneumococcal vaccination of adults in South Africa.
Vaccine description. A highly purified vaccine containing 25 ug of each of 23 capsular polysaccharides representing≥85% of the serotypes causing pneumonia and invasive pneumococcal disease in the community. Polysaccharide antigens induce type-specific antibodies that enhance opsonisation, phagocytosis and killing of pneumococci by phagocytic cells. Factors influencing the efficacy of the vaccine include the age of the individual, the state of their immune response, the presence / absence of underlying medical disorders, and the level of pneumococcal antibodies attained. Protection is only against infection caused by pneumococci of a serotype included in the vaccine,
Recommendations. Vaccination is • potentially beneficial to any individual • very effective in young otherwise healthy individuals • targeted at high-risk groups when there are cost considerations.
Evidence. Detailed literature review with emphasis on local
South African studies.
Benefits, harms, costs. • Vaccine is very effective in preventing pneumonia and invasive disease in young otherwise healthy individuals. • Efficacy is greater against bacteraemic pneumonia than against non-bacteraemic pneumonia. Efficacy may be less in the elderly aged> 65 years and in some of the high-risk categories of individuals targeted for vaccination. • Vaccine is safe with only occasional reports of anaphylaxis, although local reactions to the vaccine are quite common.
• Contraindications: Exercise care when administering the vaccine to allergic individuals. Delay immunisation if possible in the case of fever, acute disease, and relapse of chronic disease until recovery.
• Relatively few data are available on cost-effectiveness of the vaccine. However, recent studies suggest that the vaccine is cost saving in developed countries in terms of prevention of bacteraemia alone.
Validation. Endorsement by the SA Pulmonology Society, SAMA and all who attended a multidisciplinary consensus meeting to consider the draft guideline.
Financial sponsor. Development supported by an unrestricted educational grant by Pasteur Merieux Connaught to SAMA.
